Skip to main content

Advertisement

SpringerLink
Log in

Current therapeutic approaches in patients with brain metastases

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The development of brain metastases is often viewed as the end stage of a disease course and engenders skepticism about the efficacy of treatment. Aggressive management of brain metastases is effective in both symptom palliation and the prolongation of life. The majority of patients with controlled intracranial metastases will expire from systemic disease rather than from recurrence of these metastases. Single brain metastases should be treated with surgical resection or stereotactic radiosurgery, though it is unclear at this time if one modality is more effective than the other. Surgical resection is preferred when a pathologic diagnosis is needed, for tumors larger than 3.5 cm, or when immediate tumor mass decompression is required. Stereotactic radiosurgery (SRS) should be applied for single tumors less than 3.5 cm in surgically inaccessible areas and for patients who are not surgical candidates. Small tumors (ie, < 3.5 cm) that cause minimal edema and are surgically accessible may be treated with either surgery or SRS. There is controversy over whether whole brain radiation therapy (WBRT) can be omitted following surgical resection or SRS. Omission of WBRT increases intracranial tumor recurrence; however, this has not been correlated with decreased survival. Clinicians who choose to omit upfront WBRT are obligated to monitor the patient closely for intracranial recurrence, at which time further salvage therapy in the form of surgery, SRS, or WBRT may be considered. Histology is of particular importance when considering WBRT for patients with radioresistant tumors such as melanoma, renal cell carcinoma, or sarcoma. WBRT may be of less clinical benefit in this setting. Chemotherapy has been demonstrated to improve response rates when used as an adjunct to radiation therapy. These improvements in response rates have not been correlated with an improvement in median survival. Noncytotoxic radiosensitizing agents such as motexafin and efaproxiral show promise. Phase III trials to assess the benefit of motexafin in patients with metastatic lung cancer and efaproxiral in patients with metastatic breast cancer are ongoing. Targeted therapies offer promise in achieving therapeutic efficacy while minimizing side effects. Surgical adjuncts such as BCNU (carmustine) wafers and the GliaSite Radiation System (Cytyc Corporation, Marlborough, MA) may be useful in the future in achieving optimal local tumor control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Tosoni A, Ermani M, Brandes A:The pathogenesis and treatment of brain metastases:a comprehensive review. Crit Rev Oncol Hematol 2004, 55:199–215. Thorough review of the treatment modalities available for the management of brain metastases.

    Article  Google Scholar 

  2. Khuntia D, Brown P, Li J, et al.:Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006, 24:1295–1304.

    Article  PubMed  CAS  Google Scholar 

  3. Tsao M, Lloyd N, Wong R, et al.:Radiotherapeutic management of brain metastases:a systemic review and meta-analysis. Cancer Treat Rev 2005, 31:256–273.

    Article  PubMed  Google Scholar 

  4. Kirsch D, Loeffler J:Treating brain metastases:current approaches and future directions. Expert Rev Neurother 2004, 4:1015–1022.

    Article  PubMed  Google Scholar 

  5. Manon R, O'Neill A, Knisely J, et al.:Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma:an Eastern Cooperative Group Study (E 6397). J Clin Oncol 2005, 23:8870–8876.

    Article  PubMed  Google Scholar 

  6. Gaspar L, Scott C, Rotman M, et al.:Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745–751. Article subdividing the patient population with brain metastases into prognostic groups.

    Article  PubMed  CAS  Google Scholar 

  7. Wen P, Loeffler J:Management of brain metastases. Oncology 1999, 13:941–961.

    PubMed  CAS  Google Scholar 

  8. Straathof C, van den Bent M, Schmitz P, et al.:The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor. J Neurooncol 1998, 37:1–8.

    Article  PubMed  CAS  Google Scholar 

  9. Ewend M, Elbabaa S, Carey L:Current treatment paradigms for the management of patients with brain metastases. Neurosurgery 2005, 57(Suppl):S66-S77.

    Article  PubMed  Google Scholar 

  10. Arnold S, Patchell R:Diagnosis and management of brain metastases. Neuro-oncol 2001, 15:1085–1107.

    CAS  Google Scholar 

  11. Glantz M, Cole B, Forsyth P, et al.:Practice parameter:anticonvulsant prophylaxis in patients with newly diagnosed brain tumors:report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886–1893.

    PubMed  CAS  Google Scholar 

  12. Lutterbach J, Bartelt S, Ostertag C:Long-term survival in patients with brain metastases. J Cancer Res Clin Oncol 2002, 128:417–425.

    Article  PubMed  Google Scholar 

  13. Kaal E, Niel C, Vecht C:Therapeutic management of brain metastases. Lancet Neurol 2005, 4:289–298.

    Article  PubMed  Google Scholar 

  14. Arriagada R, LeChevalier T, Borie F:Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995, 87:183–190.

    Article  PubMed  CAS  Google Scholar 

  15. Stuschke M, Eberhardt W, Pottgen C:Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment:long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 1999, 17:2700–2709.

    PubMed  CAS  Google Scholar 

  16. Kondziolka D, Patel A, Lunsford L, et al.:Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999, 45:427–434.

    Article  PubMed  CAS  Google Scholar 

  17. Kondziolka D, Martin J, Flickinger J, et al.:Long-term survivors after gamma knife radiosurgery for brain metastases. Cancer 2005, 104:2785–2791.

    Article  Google Scholar 

  18. Andrews D, Scott C, Sperduto P, et al.:Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases:phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665–1672. Article describing the survival advantage of SRS and WBRT over WBRT alone in the management of solitary brain metastases.

    Article  PubMed  Google Scholar 

  19. Nam T, Lee J, Jung Y, et al.:Gamma knife surgery for brain metastases in patients harboring four or more lesions:survival and prognostic factors. J Neurosurg 2005, 102(Suppl):147–150.

    PubMed  Google Scholar 

  20. Kondziolka D, Niranjan A, Flickinger J, et al.:Radiosurgery with or without whole-brain radiotherapy for brain metastases. The patients' perspective regarding complications. Am J Clin Oncol 2005, 28:173–179.

    Article  PubMed  Google Scholar 

  21. Aoyama H, Shirato H, Nakagawa K, et al.:Interim report of the JROSG99-1 multi-institutional randomized trial, comparing radiosurgery alone vs. radiosurgery plus whole brain irradiation for 1-4 brain metastases [abstract]. J Clin Oncol 2004, 22(Suppl):1506.

    Google Scholar 

  22. Sneed P, Lamborn K, Forstner J, et al.:Radiosurgery for brain metastases:is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 1999, 43:549–558.

    Article  PubMed  CAS  Google Scholar 

  23. Hasegawa T, Kondziolka D, Flickinger J, et al.:Brain metastases treated with radiosurgery alone:an alternative to whole brain radiotherapy? Neurosurgery 2003, 52:1318–1326.

    Article  PubMed  Google Scholar 

  24. Sneed P, Suh J, Goetsch S, et al.:A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002, 53:519–526.

    Article  PubMed  Google Scholar 

  25. Pirzkall A, Debus J, Lohr F, et al.:Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 1998, 16:3563–3569.

    PubMed  CAS  Google Scholar 

  26. Mori Y, Kondziolka D, Flickinger J, et al.:Stereotactic radiosurgery for cerebral metastatic melanoma:factors affecting local disease control and survival. Int J Radiat Oncol 1998, 42:581–589.

    Article  CAS  Google Scholar 

  27. Alexander E, Moriarty T, Davis R, et al.:Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995, 87:34–40.

    Article  PubMed  Google Scholar 

  28. Weil R, Lonser R:Selective excision of metastatic brain tumors originating in the motor cortex with preservation of function. J Clin Oncol 2005, 23:1209–1217.

    Article  PubMed  Google Scholar 

  29. Patchell R, Tibbs P, Walsh J, et al.:A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494–500.

    Article  PubMed  CAS  Google Scholar 

  30. Vecht C, Haaxma-Reiche H, Noordijk E, et al.:Treatment of single brain metastasis:radiotherapy alone or combined with neurosurgery? Ann Neurol 1993, 33:583–590.

    Article  PubMed  CAS  Google Scholar 

  31. Mintz A, Kestle J, Rathbone M, et al.:A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996, 78:1470–1476.

    Article  PubMed  CAS  Google Scholar 

  32. Sills A:Current treatment approaches to surgery for brain metastases. Neurosurgery 2005, 57(Suppl 4):S24-S32.

    PubMed  Google Scholar 

  33. Patchell R, Tibbs P, Regine W, et al.:Postoperative radiotherapy in the treatment of single metastases to the brain. JAMA 1998, 280:1485–1489.

    Article  PubMed  CAS  Google Scholar 

  34. Bindal R, Sawaya R, Leavens M, et al.:Surgical treatment of multiple brain metastases. J Neurosurg 1993, 79:210–216.

    PubMed  CAS  Google Scholar 

  35. O'Neill B, Itirria N, Link M, et al.:A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 2003, 55:1169–1176.

    Article  PubMed  Google Scholar 

  36. Auchter R, Lamond J, Alexander E, et al.:A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 1996, 35:27–35.

    Article  PubMed  CAS  Google Scholar 

  37. Bindal A, Bindal R, Hess K, et al.:Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg 1996, 84:748–754.

    Article  PubMed  CAS  Google Scholar 

  38. European Organisation for Research and Treatment of Cancer website. Available at:http://www.eortc.be/protoc/Details.asp?Protocol=22952. Accessed May 1, 2006.

  39. Peereboom D:Chemotherapy in brain metastases. Neurosurgery 2005, 57(Suppl4):S54-S65.

    PubMed  Google Scholar 

  40. Crino L, Scagliotti G, De Marinis F, et al.:Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer:a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999, 17:3522–3530.

    PubMed  CAS  Google Scholar 

  41. Siena S, Landonio G, Baietta E, et al.:Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2003, 22:102.

    Google Scholar 

  42. Agarwala S, Kirkwood J, Gore M, et al.:Temozolomide for the treatment of brain metastases associated with metastatic melanoma:a phase II study. J Clin Oncol 2004, 22:2101–2107.

    Article  PubMed  CAS  Google Scholar 

  43. Ushio Y, Arita N, Hayakawa T, et al.:Chemotherapy of brain metastases from lung carcinoma:a controlled randomized study. Neurosurgery 1991, 28:201–205.

    Article  PubMed  CAS  Google Scholar 

  44. Antonadou D, Paraskevaidis M, Sarris G, et al.:Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002, 20:3644–3650.

    Article  PubMed  CAS  Google Scholar 

  45. Antonadou D, Coliarakis N, Paraskevaidis M, et al.:Whole brain radiotherapy alone or in combination with temozolomide for brain metastases:a phase III study. Proceedings from the 2002 Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2002, 54:93–94.

    Article  Google Scholar 

  46. Mehta M, Rodrigus P, Terhaard C, et al.:Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003, 21:2529–2536.

    Article  PubMed  CAS  Google Scholar 

  47. Suh J, Stea B, Nabid A, et al.:Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006, 24:1–10.

    Article  CAS  Google Scholar 

  48. Valtonen S, Timonen U, Toivanen P, et al.:Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas:a randomized double-blind study. Neurosurgery 1997, 41:44–49.

    Article  PubMed  CAS  Google Scholar 

  49. Brem S, Staller A, Wotoczek-Obadia M:Interstitial chemotherapy for local control of CNS metastases. Abstract presented at the 9th Annual Meeting of the Society of Neuro-Oncology. Toronto, ON; November 18–21, 2004.

  50. Ewend M, Brem S, Gilbert M, et al.:Treating single brain metastasis with resection, placement of BCNU-polymer wafers, and radiation therapy. Abstract presented at the 72nd Annual Meeting of the American Association of Neurological Surgeons. Toronto, ON; April 24–26, 2001.

  51. Golden GA, Meldorf M; PROLONG Study Group:Patients with metastatic brain cancer, undergoing resection and Gliadel implantation experienced low local recurrence rates in the PROLONG Registry. Abstract presented at the 9th Annual Meeting of the Society of Neuro-Oncology. Toronto, ON; November 18–21, 2004.

  52. Bogart J, Ungureanu C, Shihadeh E, et al.:Resection and permanent I-125 brachytherapy without whole brain irradiation for solitary brain metastasis from non-small cell lung carcinoma. J Neurooncol 1999, 44:53–57.

    Article  PubMed  CAS  Google Scholar 

  53. Leibel S, Gutin P, David R:Factors affecting radiation injury after interstitial brachytherapy for brain tumors. In Radiation Injury to the Nervous System. Edited by Gutin PH, Leibel SA, Sheline GE. New York:Raven Press; 1991:257–270.

    Google Scholar 

  54. Ling C, Anderson L, Shipley W:Dose inhomogeneity in interstitial implants using 125-I seeds. Int J Radiat Oncol Biol 1979, 5:419–423.

    Article  CAS  Google Scholar 

  55. Gabayan A, Green S, Sanan A, et al.:Gliasite brachytherapy for treatment of recurrent malignant gliomas:a retrospective multi-institutional analysis. Neurosurgery 2006, 58:701–709.

    Article  PubMed  Google Scholar 

  56. Ceresoli GL, Cappuzzo F, Gregorc V, et al.:Gefitinib in patients with brain metastases from non-small-cell lung cancer:a prospective trial. Ann Oncol 2004, 15:1042–1047.

    Article  PubMed  CAS  Google Scholar 

  57. Chiu C, Tsai C, Chen Y, et al.:Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005, 47:129–138.

    Article  PubMed  Google Scholar 

  58. Grossi P, Ochiai H, Archer G, et al.:Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 2003, 9:5514–5520.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology and Oncology, Wake Forest University Baptist Medical Center, Medical Center Boulevard, 27157, Winston-Salem, NC, USA

    Glenn J. Lesser MD

Authors
  1. Kevin H. Peacock MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Glenn J. Lesser MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peacock, K.H., Lesser, G.J. Current therapeutic approaches in patients with brain metastases. Curr. Treat. Options in Oncol. 7, 479–489 (2006). https://doi.org/10.1007/s11864-006-0023-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-006-0023-8

Keywords

Search

Navigation